Urgent reversal of vitamin K antagonist therapy

Acta Anaesthesiologica Scandinavica

Volumn 55, Issue 5, 2011, Pages 507-516

  Vang, M L ^a   Hvas, A M ^a   Ravn, H B ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; FRESH FROZEN PLASMA; PHENPROCOUMON; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; DRUG HALF LIFE; EMERGENCY SURGERY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 79954580544     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2011.02414.x     Document Type: Article

References (50)

1. Azar AJ, Cannegieter SC, Deckers JW, BriÃt E, van Bergen PF, Jonker JJ, Rosendaal FR., Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996; 27: 1349-55. (Pubitemid 26153278)
2. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, BriÃt E., Optimal Oral Anticoagulant Therapy in patients with mechanical heart valves. Cannegieter. N Engl J Med 1995; 333: 11-7.
3. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, BriÃt E., Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62. (Pubitemid 23205854)
4. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation andrecent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
5. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C., Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy; a systematic review and meta-analysis. Can Med Assoc J 2008; 179: 235-44.
6. Kucher N, Castellanos LR, Quiroz R, Koo S, Fanikos J, Goldhaber SZ., Time trends in warfarin-associated hemorrhage. Am J Cardiol 2004; 94: 403-6. (Pubitemid 38962721)
7. Odén A, Fahlén M., Oral anticoagulation and the risk of death: a medical record lincage study. Br Med J 2002; 325: 1073-5. (Pubitemid 35351801)
8. Ickx BE, Steib A., Perioperative management of patients receiving vitamin K antagonists. Can J Anesth 2006; 53: 113-22.
9. Levy JH, Tanaka KA, Dietrich W., Perioperative hemostatic management of patients treated with vitamin K Antagonists. Anaesthesiology 2008; 109: 918-26.
10. Hanley JP., Warfarin reversal. J Clin Pathol 2004; 57: 1132-9. (Pubitemid 39486516)
11. Lassen JF, Kjeldsen J, Antonsen S, Hyltoft Petersen P, Brandslund I., Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy. Clin Chem 1995; 41: 1171-6.
12. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE., Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160: 1612-7. (Pubitemid 30367900)
13. Lassen JF, Brandslund I, Antonsen S., International normalized ratio for prothrombin times in patients taking oral anticoagulants; critical difference and probability of significant change in consecutive measurements. Clin Chem 1995; 41: 444-7.
14. Van Geest-Daalderop JH, Péquériaux NC, Van den Besselaar AM., Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements. Thromb Haemost 2009; 102: 588-92.
15. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J., American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 299S-339S. (Pubitemid 351894915)
16. Gage BF, Walerman AD, Shannon W, Brechler M, Rich MW, Radford MJ., Validation of clinical classification Schemes for Predicting Stroke. J Am Med Assoc 2001; 285: 2864-70.
17. Kearon C, Hirsh J., Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-11.
18. Torn M, Rosendaal FR., Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003; 123: 676-82.
19. Brody DL, Aiyagari V, Shackleford AM, Diringer MN., Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2: 263-7. (Pubitemid 41112397)
20. Conti S, La Torre D, Gambelunghe G, Ciorba E, Iorio A., Successful treatment with rFVIIa of spontaneous intracranial hemorrhage in patient with mechanical prosthetic heart valves. Clin Lab Haematol 2005; 27: 283-5. (Pubitemid 41113504)
21. Makris M, Watson HG., The management of coumarin-induced over-anticoagulation. Annotation. Br J Haematol 2001; 114: 271-80.
22. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC., Intravenous versus subcutaneous vitamin K in reversing excessive oral anticoagulation. Am J Cardiol 1999; 83: 286-8. (Pubitemid 29047318)
23. Garcia DA., The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006; 47: 804-8. (Pubitemid 43243105)
24. Makris M, van Veen JJ, Maclean R., Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Trombolysis 2010; 29: 171-81.
25. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E., The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-33S. (Pubitemid 39297955)
26. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J., Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998; 79: 1116-8. (Pubitemid 28297157)
27. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J., Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356: 1551-3.
28. Bhavnani M, Shwe K., The use of oral vitamin K for reversal of over-warfarinization. Br J Haematol 2001; 113: 839-40. (Pubitemid 32524412)
29. Poli D, Antonucci E, Lombardi A, Gensini GF, Abbate R, Prisco D., Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation. Haematologica 2003; 88: 237-8. (Pubitemid 37101511)
30. Dentali F, Crowther MA., Management of excessive anticoagulant effect due to vitamin K antagonists. hematology. Am Soc Hematol Educ Program 2008; 1: 266-70.
31. Benson AB, Moss M, Silliman CC., Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol 2009; 147: 431-43.
32. Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006; 132: 277-85. (Pubitemid 43381534)
33. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE., Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 9-16. (Pubitemid 350025993)
34. Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H., Beriplex P/N Anticoagulation Reversal Study Group. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol 2010; 89: 309-16.
35. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP., Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010; 41: 48-53.
36. Rosovsky RP, Crowther MA., What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008; 1: 36-8.
37. Kalina M, Tinkoff G, Gbadebo A, Veneri P, Fulda G., A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg 2008; 74: 858-61.
38. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T., Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37: 1465-70. (Pubitemid 44305727)
39. Sjöblom L, HÃ¥rdemark HG, Lindgren A, Norrving B, Fahlén M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J., Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001; 32: 2567-74. (Pubitemid 33055307)
40. Cartmill M, Dolan G, Byrne JL, Byrne PO., Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-61.
41. Boulis NM, Bobek MP, Schmaier A, Hoff JT., Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-8.
42. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF., Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80. (Pubitemid 27121012)
43. Fredriksson K, Norrving B, Strömblad LG., Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-7.
44. Pabinger-Fasching I., Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res 2008; 122: 19-22.
45. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H, Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-31. (Pubitemid 351404929)
46. Lorenz R, Kienast J, Otto U, Kiehl M, Schreiter D, Haertel S, Barthels M., Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. Blood Coagul Fibrinolysis 2007; 18: 565-70. (Pubitemid 47344305)
47. Preston FE, Laidlaw ST, Sampson B, Kitchen S., Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-24. (Pubitemid 34178663)
48. Van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Stengers PF., Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-20. (Pubitemid 44173049)
49. Yasaka M, Sakata T, Naritomi H, Minematsu K., Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 455-9. (Pubitemid 40409977)
50. Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K., Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol 2003; 82: 121-3. (Pubitemid 36700988)